Strong growth in the Libre CGM segment, with sales surpassing $1.6 billion. Abbott is targeting high single-digit top-line growth in 2025. Abbott Laboratories demonstrated solid performance in Q3 ...

Abbott Laboratories’ ABT growth in the fourth quarter of 2024 can be attributed to strong improvement in global Core ...

Senseonics announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.

Abbott (NYSE:ABT) today unveiled a new initiative addressing the biases and stigmas associated with diabetes management.

In the past few years, some high-profile dividend stocks have reduced their payouts, much to the chagrin of investors. As ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS increase.

Abbott Laboratories is a well-diversified health care company, with four distinct units: medical devices, diagnostics, nutrition and ...

The FreeStyle Libre 3 system helped Nathan manage his diabetes. Now, he's sharing his story to help lift stigma.Abbott NORTHAMPTON, MA / ACCESS Newswire / February 7, 2025 / As a competitive powerlift ...

The upbeat results demonstrate DexCom’s position as a key player in the continuous glucose monitoring (CGM ... has gained 8.5% while its peer Abbott Laboratories ABT inched up 0.3%.DXCM has ...